Concepedia

Author

Vani Lakshminarayanan

Mayo Clinic in ArizonaORCID

Also Known As

V. Lakshminarayanan, Vani Lakshminarayanan

13

Publications

541

Citations

7

H-Index

18

Concepts

All Affiliations

Mayo Clinic in ArizonaUniversity of Georgia
VL

About

Vani Lakshminarayanan is an author at Mayo Clinic in Arizona specializing in medicine, tumor biology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

75

2

Cell Biology

2

2

75

3

Immunology

2

2

75

4

Autoimmunity

2

2

75

5

Pathology

1

1

65

Vani Lakshminarayanan

×

7

Publications

538

Citations

7

H-Index

YearCitations

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

Vani Lakshminarayanan, Pamela Thompson, Margreet A. Wolfert,

Proceedings of the National Academy of Sciences

2011

298

Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist

Abu‐Baker M. Abdel‐Aal, Vani Lakshminarayanan, Pamela Thompson,

ChemBioChem

2014

65

Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide

Pamela Thompson, Vani Lakshminarayanan, Nitin T. Supekar,

Chemical Communications

2015

61

MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice

Vani Lakshminarayanan, Nitin T. Supekar, Jie Wei,

PLoS ONE

2016

51

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

Kristen Sweet, Qingxuan Song, Matthew J. Loza,

RMD Open

2021

36

Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide

Nitin T. Supekar, Vani Lakshminarayanan, Chantelle J. Capicciotti,

ChemBioChem

2017

17

Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes

Latha Pathangey, Vani Lakshminarayanan, Vera J. Suman,

Biomolecules

2016

10

Page 1